An encouraging cash flow report, but by removing the $1.3M Mundipharma payment from customer revenue we see only $200K revenue for other activities. On my analysis Aspen has not yet bought any packaged Fleurstat and the condom market is stalled completely. This $200K can easily be accounted for by product manufactured for DEP partners, as mentioned in the report.
I look forward keenly to reports in FYE 2019 where the income exceeds the expenditure!
Ann: Quarterly Cashflow Report, page-3
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |